In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Short NVO slightly under 91.41, target n/a, stop loss @ 91.67 Check the time stamp on this data. Updated AI-Generated Signals ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Ameritas Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 453.3% during ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...